🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Brain Cancer Metastatic

ioMRI in the Surgery of Brain Metastases. NCT07197632NA1 site📍 Munich Technical University of Munich · Tests: Surgery with intraoperative MRI Neoadjuvant Stereotactic Radiotherapy for Brain Metastasis NCT06933199NA4 sites📍 Ostrava📍 Brno📍 Hradec Králové University Hospital Ostrava · Tests: Neoadjuvant Stereotactic Radiotherapy (NaSRT), Postoperative Stereotactic Radiotherapy (SRT) A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases NCT05033691NA1 site📍 Jerusalem Hadassah Medical Organization · Tests: Stereotactic surgery Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer NCT06072807Phase 41 site📍 New York Weill Medical College of Cornell University · Tests: Brain Imaging with 18F-FES Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases NCT05866432Phase 21 site📍 Vienna Medical University of Vienna · Tests: Datopotamab deruxtecan Feasibility of Intra- and Post-operative Microdialysis During Neurosurgery for Central Nervous System Lesions NCT04047264NA1 site📍 Rochester Mayo Clinic · Tests: Microdialysis, Magnetic Resonance Imaging, Computed Tomography EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active NCT06649058Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Systemic Therapy, Stereotactic Radiosurgery DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs NCT06176261Phase 23 sites📍 Miami📍 Boston📍 Durham Nancy Lin, MD · Tests: Datopotamab Deruxtecan Combined Gamma Knife/Linac Radiosurgery for Large Brain Tumors / Metastases NCT07162246Phase 21 site📍 Toronto Sunnybrook Health Sciences Centre · Tests: Radiation Therapy WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases NCT06243003Phase 1, Phase 21 site📍 Shanghai Fudan University · Tests: HA-WBRT plus SBRT Asciminib in HER2+ Breast Cancer Brain Metastases NCT07136428Phase 1, Phase 21 site📍 Durham Duke University · Tests: Asciminib and Trastuzumab Evaluation of the CONVIVO System NCT05139277NA1 site📍 Lebanon Dartmouth-Hitchcock Medical Center · Tests: CONVIVO system, Conventional histologic evaluation A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) NCT07492680Phase 258 sites📍 San Francisco📍 Aurora📍 Atlanta Bristol-Myers Squibb · Tests: BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC, Temozolomide, Pumitamig Pilot IntraOperative Neuronal Electrophysiology in Tumor rElatEd suRgery NCT06617208NA1 site📍 Rotterdam Erasmus Medical Center · Tests: Neuropixel probe recording A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors NCT07361562Phase 115 sites📍 Scottsdale📍 Scottsdale📍 New Haven Cogent Biosciences, Inc. · Tests: CGT4255 A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases NCT06764940Phase 212 sites📍 Duarte📍 Los Angeles📍 San Diego Biostar Pharma, Inc. · Tests: Utidelone, Utidelone in combination with capecitabine, Utidelone in combination with capecitabine, Utidelone in combina… Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases NCT06857006NA1 site📍 Birmingham University of Alabama at Birmingham · Tests: brain metastases radiosurgery Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases NCT05911230NA1 site📍 Basel University Hospital, Basel, Switzerland · Tests: Advanced diffusion-weighted MRI (ADW-MRI) 18F-FLUC PET/MR in Patients With Brain Mets NCT06159335Phase 31 site📍 Madison University of Wisconsin, Madison · Tests: F-Fluciclovine radiotracer Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis NCT06315010Phase 217 sites📍 Graz📍 Vienna📍 München MedSIR · Tests: Repotrectinib A Ketogenic Diet as a Complementary Treatment on Patients With High-grade Gliomas and Brain Metastases NCT05564949NA2 sites📍 Chaïdári📍 Athens Attikon Hospital · Tests: CKD Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) NCT04427384n/a54 sites📍 Phoenix📍 Little Rock📍 Castro Valley GT Medical Technologies, Inc. · Tests: GammaTile Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM) NCT07053033Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Surgery, LITT A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer NCT07506109Phase 24 sites📍 Beijing📍 Wuhan📍 Chengdu Tianjin Medical University Cancer Institute and Hospital · Tests: Ipilimumab N01, Sintilimab, Cetuximab, Dabrafenib A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases NCT06136884Phase 16 sites📍 Detroit📍 Oklahoma City📍 Charleston A2A Pharmaceuticals Inc. · Tests: AO-252 Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors NCT05831631n/a1 site📍 Milan Pietro Mortini, MD, Prof. · Tests: Circulating leukocytes immunophenotype, Tumor sampling A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases NCT07268053EARLY Phase 11 site📍 Phoenix Nader Sanai · Tests: Risvutatug rezetecan Cancer Genetic Testing in Ethnic Populations NCT04475640NA2 sites📍 Scottsdale📍 Jacksonville Mayo Clinic · Tests: Biospecimen Collection, Genetic Testing MRI Screening for Brain Metastases Among Patients With Triple Negative or HER2+ Stage II or III Breast Cancer NCT06247449NA1 site📍 Toronto Sunnybrook Health Sciences Centre · Tests: Brain imaging, Analysis of circulating tumor DNA, Testing Morbidities Index Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma NCT06796543NA3 sites📍 Washington D.C.📍 Baltimore📍 Minneapolis Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: Consolidative radiation therapy (cRT)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy